Davutamig Biosimilar – Anti-Tyrosine-protein kinase Met mAb – Research Grade

Introduction

Davutamig biosimilar is a novel therapeutic antibody that targets the tyrosine-protein kinase Met (c-Met) receptor. This antibody is designed to mimic the function of the naturally occurring anti-c-Met monoclonal antibody and has shown promising results in preclinical studies. In this article, we will discuss the structure, activity, and potential applications of Davutamig biosimilar in the field of cancer research.

Structure of Davutamig Biosimilar

Davutamig biosimilar is a recombinant monoclonal antibody that is produced by genetically modifying Chinese hamster ovary (CHO) cells. It has a molecular weight of approximately 150 kDa and is composed of two heavy chains and two light chains. The heavy chains are linked by disulfide bonds and consist of four constant domains (CH1, CH2, CH3, and CH4) and one variable domain (VH). The light chains are also linked by disulfide bonds and consist of two constant domains (CL) and one variable domain (VL). The variable domains of the heavy and light chains are responsible for binding to the c-Met receptor.

Activity of Davutamig Biosimilar

The c-Met receptor is a transmembrane protein that is overexpressed in many types of cancer, including lung, breast, and liver cancer. It plays a crucial role in cell proliferation, survival, and migration, making it an attractive therapeutic target for cancer treatment. Davutamig biosimilar binds to the extracellular domain of the c-Met receptor and blocks its activation by its natural ligand, hepatocyte growth factor (HGF). This prevents the downstream signaling pathways that promote cancer cell growth and survival, ultimately leading to tumor regression.

In addition to blocking c-Met signaling, Davutamig biosimilar also has an antibody-dependent cellular cytotoxicity (ADCC) activity. This means that it can bind to immune cells, such as natural killer (NK) cells, and induce them to kill cancer cells that express the c-Met receptor. This dual mechanism of action makes Davutamig biosimilar a potent anti- cancer agent.

Applications of Davutamig Biosimilar

Davutamig biosimilar is currently being investigated as a potential treatment for various types of cancer. In preclinical studies, it has shown efficacy in inhibiting the growth of lung, breast, and liver cancer cells. It has also been shown to enhance the anti-tumor effects of other chemotherapeutic agents, making it a potential combination therapy option.

In addition to its use as a monotherapy or combination therapy for cancer treatment, Davutamig biosimilar also has potential applications in diagnostic imaging. The c-Met receptor is highly expressed in cancer cells and can be visualized using radiolabeled antibodies. This allows for non-invasive imaging of tumors and can aid in the early detection and monitoring of cancer progression.

Conclusion

In conclusion, Davutamig biosimilar is a novel therapeutic antibody that targets the c-Met receptor. Its unique structure and dual mechanism of action make it a promising candidate for the treatment of various types of cancer. In addition, its potential applications in diagnostic imaging further highlight its versatility and potential impact in the field of cancer research. Further clinical studies are needed to fully evaluate the efficacy and safety of Davutamig biosimilar, but early results are promising and warrant further investigation.

ProteoGenix catalogue number PX-TA1940. For research use only.

Target: Davutamig Biosimilar – Anti-Tyrosine-protein kinase Met mAb – Research Grade; Clonality: Monoclonal Antibody; Expression system: XtenCHO; Buffer: 0.01M PBS, pH 7.4; Applications: ELISA, WB.

Available configurations: 50ug, 100ug, 1mg.

Download the manufacturer datasheet